Alembic's Aleor joint venture gets FDA approval for generic Clobex

Press enter to search
Close search
Open Menu

Alembic's Aleor joint venture gets FDA approval for generic Clobex

By Sandra Levy - 10/22/2019

Alembic’s joint venture Aleor Dermaceuticals has received the Food and Drug Administration’s green light for clobetasol propionate spray, 0.05%.

The product is the generic of Galderma’s Clobex spray, 0.05%.

Clobetasol propionate spray, 0.05% is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area in patients 18 years of age or older.

Clobetasol propionate spray, 0.05%, had a market value of roughly $22 million for the 12 months ended December 2018, according to IQVIA.

RELATED TOPICS